ANAPTYSBIO, INC (ANAB): Submission of Matters to a Vote of Security Holders
ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 11, 2026, AnaptysBio, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class III directors, Hollings Renton and John P. Schmid,
How this was made
The 30-second read
Why it matters
Voting results confirm governance actions: two Class III director elections, ratification of KPMG as independent auditor for FY ending June 30, 2027, non-binding advisory approval of executive compensation, and approval of an amendment to the 2017 Equity Incentive Plan.
Market read
This is a routine disclosure of shareholder vote results, with no new financial metrics or strategic transaction described.
What to watch
Traders may be watching for any separate, contemporaneous disclosures (e.g., financing, clinical updates, or executive changes) that are not included in this 8-K item.
Background
The company submitted an SEC Form 8-K under Item 5.07 to report matters voted on by stockholders at its 2026 annual meeting.
Ticker impact
AnaptysBio filed an 8-K reporting the results of its Aug. 11, 2026 annual meeting votes, including director elections and equity plan amendment approval.
Limited near-term impact; any reaction is likely small and short-lived unless investors were specifically focused on the equity plan amendment or board changes.
The 8-K discloses voting outcomes (directors, auditor ratification, advisory say-on-pay, and equity incentive plan amendment) without new guidance, financial results, or material transactions.
Market effects
No clear sector read-through; this is company-specific governance and plan approval.
None indicated.
None indicated.
Counterpoint
If the equity incentive plan amendment was contentious, the vote outcome could marginally affect sentiment around dilution expectations, but the filing provides no new quantitative details.
Key entities
- issuerAnaptysBio, Inc.
Subject of the 8-K; reported stockholder vote outcomes from its Aug. 11, 2026 annual meeting.
- director_nomineeHollings Renton
Elected as a Class III director for a three-year term.
- director_nomineeJohn P. Schmid
Elected as a Class III director for a three-year term.
- auditorKPMG LLP
Ratified as independent registered public accounting firm for FY ending June 30, 2027.
